TALEN

TALEN1-fosl2

ID

ZDB-TALEN-160323-1

Name

TALEN1-fosl2

Previous Names

None

Target

fosl2 (1)

Target Sequence 1

5' - TACGACACATCCTCCCGC - 3'

Target Sequence 2

5' - TGGTGTCCGGGTGCGCCG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
fb15	fosl2
fb16	fosl2

Expression

Gene expression in Wild Types + TALEN1-fosl2

No data available

Phenotype

Phenotype resulting from TALEN1-fosl2

No data available

Phenotype of all Fish created by or utilizing TALEN1-fosl2

Phenotype	Fish	Conditions	Figures
anatomical structure Ab1-fosl2 labeling absent, abnormal	fosl2^fb15/fb15	standard conditions	Fig. 1 from Jahangiri et al., 2016
whole organism fosl2 expression decreased amount, abnormal	fosl2^fb15/fb15	standard conditions	Fig. 1 from Jahangiri et al., 2016
bulbus arteriosus smooth muscle ab1-elnb labeling absent, abnormal	fosl2^fb15/fb15	standard conditions	Fig. 2 from Jahangiri et al., 2016
heart ltbp3 expression increased amount, abnormal	fosl2^fb16/fb16	control	Fig. 3 from Jahangiri et al., 2016
anatomical structure Ab1-fosl2 labeling absent, abnormal	fosl2^fb16/fb16	standard conditions	Fig. 1 from Jahangiri et al., 2016
whole organism ltbp3 expression increased amount, abnormal	fosl2^fb16/fb16	control	Fig. 3 from Jahangiri et al., 2016
whole organism mef2cb expression increased amount, abnormal	fosl2^fb16/fb16	control	Fig. 3 from Jahangiri et al., 2016
heart ltbp3 expression increased distribution, abnormal	fosl2^fb16/fb16	control	Fig. 3 from Jahangiri et al., 2016
cardiac ventricle decreased size, abnormal	fosl2^fb15/fb15; f1Tg	standard conditions	Fig. 1 from Jahangiri et al., 2016
cardiac ventricle cardiac muscle cell decreased amount, abnormal	fosl2^fb15/fb15; f2Tg	standard conditions	Fig. 2 from Jahangiri et al., 2016
bulbus arteriosus muscle precursor cell increased amount, abnormal	fosl2^fb16/fb16; f1Tg; fb7Tg	control	Fig. 3 from Jahangiri et al., 2016
cardiac ventricle cardiac muscle cell decreased amount, abnormal	fosl2^fb16/fb16; f2Tg	standard conditions	Fig. 2 from Jahangiri et al., 2016
cardiac ventricle cardiac muscle tissue growth decreased rate, abnormal	fosl2^fb16/fb16; hsc6Tg	standard conditions	Fig. 3 from Jahangiri et al., 2016
cardiac ventricle cardiac muscle tissue growth hypotrophic growth, abnormal	fosl2^fb16/fb16; hsc6Tg	standard conditions	Fig. 3 from Jahangiri et al., 2016
cardiac ventricle cardiac muscle tissue growth increased rate, abnormal	fosl2^fb16/fb16; hsc6Tg	standard conditions	Fig. 5 from Jahangiri et al., 2016

Citations